Adenylosuccinic acid tetraammonium Adenylosuccinate tetraammonium; Aspartyl adenylate tetraammonium|西域试剂

Adenylosuccinic acid tetraammonium Adenylosuccinate tetraammonium; Aspartyl adenylate tetraammonium,98.0%

产品编号：Bellancom-127137A| 分子式：C₁₄H₃₀N₉O₁₁P| 分子量：531.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-127137A		￥9000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Adenylosuccinic acid tetraammonium Adenylosuccinate tetraammonium; Aspartyl adenylate tetraammonium

产品介绍

Adenylosuccinic acid tetraammonium (Adenylosuccinate; Aspartyl adenylate) 是一种具有口服活性的嘌呤核糖核苷单磷酸，在核苷酸循环代谢 (nucleotide cycle metabolite) 中起作用。Adenylosuccinic acid tetraammonium 可以通过腺苷琥珀酸裂解酶转化成富马酸。Adenylosuccinic acid tetraammonium 有潜力用于杜氏肌营养不良症 (DMD) 的研究。

生物活性

Adenylosuccinic acid tetraammonium (Adenylosuccinate; Aspartyl adenylate) is an orally active purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid tetraammonium can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid tetraammonium has the potential for the study of duchenne muscular dystrophy(DMD).

体外研究

体内研究

Adenylosuccinic acid tetraammonium (oral administration; 3-3000 µg/mL; 6 weeks) significantly improves the features of murine DMD, it decreases the number of centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca²⁺ content of mdx tibialis anterior.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57Bl/10ScSn (normal wild-type strain; Con) and C57Bl/10mdx (mdx) mice
Dosage:	3 µg/mL, 30 µg/mL, 300 µg/mL, 3000 µg/mL
Administration:	3 µg/mL for 3 days and 30 µg/mL for the next 4 days, and 300 µg/mL for one week, and then 3000 µg/mL for 6 weeks
Result:	Ameliorated the symptoms of murine duchenne muscular dystrophy.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57Bl/10ScSn (normal wild-type strain; Con) and C57Bl/10mdx (mdx) mice
Dosage:	3 µg/mL, 30 µg/mL, 300 µg/mL, 3000 µg/mL
Administration:	3 µg/mL for 3 days and 30 µg/mL for the next 4 days, and 300 µg/mL for one week, and then 3000 µg/mL for 6 weeks
Result:	Ameliorated the symptoms of murine duchenne muscular dystrophy.

性状

Solid

溶解性数据

In Vitro:

H₂O : 200 mg/mL (376.35 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8818 mL	9.4088 mL	18.8175 mL
5 mM	0.3764 mL	1.8818 mL	3.7635 mL
10 mM	0.1882 mL	0.9409 mL	1.8818 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献